← Leaderboards
Michael R Rickels
University Of Pennsylvania
$10,133,718
Attributed
$14,108,333
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,108,333 · 10
By mechanism
R01$10,113,134 · 4
P30$1,968,978 · 2
U01$1,787,232 · 1
R56$147,020 · 1
M01$91,969 · 2
Top collaborators
- Andrea Bridget Kelly6 shared
- Naomi Sage Chaytor5 shared
- Yogish C. Kudva5 shared
- Richard E Pratley5 shared
- Robert J Henderson3 shared
- Kellee Miller2 shared
- Ruth S Weinstock1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Maureen G Maguire$56,247,702
- Stuart L Fine$3,584,878
- Julio Alonso Chirinos Medina$12,868,016
- Franz M Matschinsky$8,733,505
- Thomas P Cappola$16,895,234
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusInsulinAdultIsletGlucoseGlucagonBeta CellRandomizedMortalityAlpha CellInsulin SecretionGlycemic ControlHypoglycemiaTechnologyInsulin-Dependent Diabetes MellitusGenerationsResponseGlucose MonitorInflammationNon-Insulin-Dependent Diabetes MellitusParticipantCell PhysiologyHormonesDefect
Grant awards (38)
Restoring awareness of hypoglycemia in type 1 diabetes$568,303
U01 · FY2025 · DK · contact PI
Radioimmunoassay and Biomarkers Core$210,885
P30 · FY2025 · DK · contact PI
Restoring awareness of hypoglycemia in type 1 diabetes$813,114
U01 · FY2024 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$631,227
R01 · FY2024 · DK
Radioimmunoassay and Biomarkers Core$210,956
P30 · FY2024 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$672,124
R01 · FY2023 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$239,044
R01 · FY2023 · DK
Radioimmunoassay and Biomarkers Core$210,956
P30 · FY2023 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$682,845
R01 · FY2022 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$565,751
R01 · FY2022 · DK
Restoring awareness of hypoglycemia in type 1 diabetes$405,815
U01 · FY2022 · DK · contact PI
Radioimmunoassay and Biomarkers Core$212,953
P30 · FY2022 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$689,687
R01 · FY2021 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$638,470
R01 · FY2021 · DK
Radioimmunoassay/Biomarkers Core$224,374
P30 · FY2021 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$692,825
R01 · FY2020 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$657,345
R01 · FY2020 · DK
Glucose counterregulation in long standing type 1 diabetes$401,769
R01 · FY2020 · DK · contact PI
Radioimmunoassay/Biomarkers Core$224,374
P30 · FY2020 · DK · contact PI
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$660,368
R01 · FY2019 · DK
Glucose counterregulation in long standing type 1 diabetes$401,769
R01 · FY2019 · DK · contact PI
Radioimmunoassay/Biomarkers Core$224,374
P30 · FY2019 · DK · contact PI
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.$147,020
R56 · FY2019 · DK
Glucose counterregulation in long standing type 1 diabetes$401,769
R01 · FY2018 · DK · contact PI
Radioimmunoassay/Biomarkers Core$224,374
P30 · FY2018 · DK · contact PI
Glucose counterregulation in long standing type 1 diabetes$401,769
R01 · FY2017 · DK · contact PI
Radioimmunoassay/Biomarkers Core$225,732
P30 · FY2017 · DK · contact PI
Glucose counterregulation in long standing type 1 diabetes$401,769
R01 · FY2016 · DK · contact PI
Glucose Counterregulation in Long Standing Type 1 Diabetes$347,849
R01 · FY2015 · DK · contact PI
Glucose Counterregulation in Long Standing Type 1 Diabetes$347,849
R01 · FY2014 · DK · contact PI
Glucose Counterregulation in Long Standing Type 1 Diabetes$335,674
R01 · FY2013 · DK · contact PI
Glucose Counterregulation in Long Standing Type 1 Diabetes$349,799
R01 · FY2012 · DK · contact PI
Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human$178,605
R01 · FY2012 · DK · contact PI
Glucose Counterregulation in Long Standing Type 1 Diabetes$414,827
R01 · FY2011 · DK · contact PI
INVESTIGATION OF BETA CELL FUNCTION IN ISLET CELL TRANSPLANTATION$28,633
M01 · FY2005 · RR
INVESTIGATION OF COUNTERREGULATORY HORMONAL RESPONSIVENESS IN ISLET CELL$13,976
M01 · FY2005 · RR
Investigation of beta cell function in islet cell transplantation$33,735
M01 · FY2004 · RR
Investigation of Counterregulatory Hormonal Responsiveness in Islet Cell$15,625
M01 · FY2004 · RR